1
|
Roulin L, Jais J, Poullot E, Robe C, Scherman E, Lemonnier F, Le Bras F, Maarek A, Belhadj K, Dupuis J, Hammoud M, El Gnaoui T, Mule S, Itti E, Delfau-Larue M, Gaulard P, Haioun C, Copie-Bergman C. CLINICAL, IMMUNOPHENOTYPIC AND GENETIC CHARACTERISTICS OF AGGRESSIVE (NON-BURKITT) B-CELL LYMPHOMA IN A REAL LIFE COHORT. Hematol Oncol 2019. [DOI: 10.1002/hon.13_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Roulin
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - J. Jais
- Biostatistics; Necker Hospital, APHP; Paris France
| | - E. Poullot
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | - C. Robe
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | | | - F. Lemonnier
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - F. Le Bras
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - A. Maarek
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - K. Belhadj
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - J. Dupuis
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - M. Hammoud
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - T. El Gnaoui
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - S. Mule
- Radiology Department; Henri Mondor Hospital, APHP; Créteil France
| | - E. Itti
- Nuclear Medicine Department; Henri Mondor Hospital, APHP; Créteil France
| | - M. Delfau-Larue
- Immunobiology and Haematology Department; Henri Mondor Hospital, APHP; Créteil France
| | - P. Gaulard
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| | - C. Haioun
- Lymphoid malignancies Unit; Henri Mondor Hospital, APHP; Créteil France
| | - C. Copie-Bergman
- Pathology Department; Henri Mondor Hospital, APHP; Créteil France
| |
Collapse
|
2
|
Prot-Bertoye C, Lebbah S, Daudon M, Tostivint I, Jais J, Traxer O, Knebelmann B, Courbebaisse M. Objectifs thérapeutiques et effets indésirables des traitements médicamenteux de la cystinurie : résultats de l’étude nationale française portant sur 442 patients. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Huet S, Tesson B, Jais J, Feldman A, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Xerri L, Ansell S, Tarte K, Boyault S, Haioun C, Link B, Feugier P, Lopez-Guillermo A, Brice P, Hayette S, Jardin F, Offner F, Gentien D, Viari A, Campo E, Cerhan J, Salles G. GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Huet
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Tesson
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - J. Jais
- Biostatistiques; Institut Carnot-Calym; Pierre-Bénite France
| | - A.L. Feldman
- Department of Laboratory Medicine and Pathology, Mayo Clinic; Rochester USA
| | - L. Magnano
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - E. Thomas
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - A. Traverse-Glehen
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - B. Albaud
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - L. Xerri
- Department of Bio-Pathology, Institut Paoli-Calmettes; Aix-Marseille University; Marseille; France
| | - S. Ansell
- Hematology; Mayo Clinic; Rochester USA
| | - K. Tarte
- INSERM U917; Université Rennes 1, EFS Bretagne, CHU Rennes; Rennes France
| | - S. Boyault
- Département de Recherche Translationnelle et d'Innovation, Génomique des Cancers, Centre Léon Bérard; Lyon France
| | - C. Haioun
- Unité Hémopathies Lymphoïdes; Assistance Publique-Hopitaux de Paris; Créteil France
| | - B. Link
- Department of Medicine; University of Iowa; Iowa City USA
| | - P. Feugier
- Hematology; Nancy University Hospital; Vandoeuvre-Lès-Nancy France
| | - A. Lopez-Guillermo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - P. Brice
- Hématologie; Assistance Publique-Hopitaux de Paris; Paris France
| | - S. Hayette
- Laboratoire d'Hématologie; Hospices Civils de Lyon; Pierre-Bénite France
| | - F. Jardin
- Inserm U1245, Henri Becquerel Comprehensive Cancer Center; Rouen France
| | - F. Offner
- Hematology; Universitat Ziekenhuis Gent; Ghent Belgium
| | - D. Gentien
- Translational Research Department, Genomic platform, Institut Curie; PSL Research University; Paris France
| | - A. Viari
- Plateforme de Bioinformatique 'Gilles Thomas', Synergie Lyon Cancer; Lyon France
| | - E. Campo
- Department of Anatomic Pathology, Hospital Clinic, IDIBAPS, Ciberonc; University of Barcelona; Barcelona Spain
| | - J.R. Cerhan
- Department of Health Sciences Research; Mayo Clinic; Rochester USA
| | - G. Salles
- Service d'hématologie Marcel Bérard; CHLS, Hospices Civils de Lyon; Pierre-Bénite France
| |
Collapse
|
4
|
Delfau-Larue M, Beldi-Ferchiou A, Jais J, Godard N, Salles G, Casasnovas R, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Sebban C, Bouabdallah R, Gonzalez H, Corront B, Oberic L, Briere J, Gaulard P, Coiffier B, Thieblemont C. LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - A. Beldi-Ferchiou
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - J. Jais
- Biostatistics Unit, APHP; Univ Paris Descartes; Paris France
| | - N. Godard
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - G.A. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre-Benite France
| | - R. Casasnovas
- Hematology; CHU Dijon - Hopital du Bocage; Dijon France
| | - H. Tilly
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - C. Fruchart
- Institut d'Hématologie de Basse Normandie; CHU Caen; Caen France
| | | | - C. Haioun
- Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor; Creteil France
| | - J. Lazarovici
- Clinical Hematology, Gustave Roussy Cancer Center; Villejuif France
| | - A. Perrot
- Hematology department, CHU Brabois; Vandoeuvre les Nancy France
| | - C. Sebban
- Onco Hematology; Centre Leon Berard; Lyon France
| | - R. Bouabdallah
- Onco Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Corront
- Hematology; CH Annecy Genevois, Epagny Metz-Tessy; France
| | - L. Oberic
- Hematology; IUC - Oncopole CHU Toulouse; Toulouse France
| | - J. Briere
- Pathology; APHP, Hopital Saint-Louis; Paris France
| | - P. Gaulard
- Pathology; APHP, Hopital Henri Mondor; Creteil France
| | - B. Coiffier
- CNRS UMR5239; Centre Hospitalier Lyon Sud; Pierre Benite France
| | - C. Thieblemont
- Hemato-Oncology, APHP; Hopital Saint-Louis; Paris France
| |
Collapse
|
5
|
Billemont B, Hornecker M, Ropert S, Blanchet B, Jais J, Blanchard P, Meric J, Alexandre J, Tod M, Goldwasser F. Correlation of sorafenib plasma concentrations and clinical toxicity: A prospective population pharmacodynamic and pharmacokinetic study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14585] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14585 Background: Sorafenib is an angiogenesis inhibitor recently approved for the treatment of metastatic renal cell carcinoma and hepatocarcinoma. This oral multi-targeted kinase inhibitor blocks the VEGF, PDGF receptors, BRAF and c-kit. In clinical trials, severe toxicities included rash, hand-foot syndrome and diarrhea. We investigated the relationship between severe toxicity and sorafenib plasmatic exposure. Patients and methods: From February 2008 to December 2008, 32 patients (pts) were treated with sorafenib (800 mg given daily). Clinical and blood exams were performed at baseline and every 2 weeks. Toxicity events were graded according to National Cancer Institute Common Toxicity Criteria 3.0. The sorafenib area under the plasma concentration-time curve over 12 hours (AUC0–12) was determined every 2 weeks by gradient elution liquid chromatography, data analysis with one-compartment disposition and a population approach using NONMEM software. Grade 3 toxicity free survival was estimated by Kaplan-Meier method. Results: Pts (23 males), ECOG 0–1 (27 pts), median age 62.8 years (range 37–78), with metastatic hepato-carcinoma (11), melanoma (6), thyroid cancer (8), renal cell carcinoma (7), received a median treatment duration of 94 days (range : 7–330). 20 pts experienced grade 3 toxicities with 33 events: hand-foot hyperkeratosis (14), diarrhea (5), cutanous rash (4), asthenia (2), anorexia (2), dyspnea (1), scrotal toxicity (1), post surgical complication (1), hypertension (1), increase creatinine level (1), digestive hemorrhage (1). The median AUC0–12 was 62.4 mg/L.h, ranging from 28.7 to 202.2 mg/L.h. Amongst pts experiencing grade 3 toxicity, two groups of 16 pts were defined with the median AUC0- 12 as cut off: low exposure (Lw) and high exposure (Hi). Six Lw pts experienced grade 3 toxicity versus 14 Hi pts (exact Fisher Test p=0.009). The probability of free grade 3 toxicity survival was higher for Lw (Logrank test p=0.004). Conclusions: These results show that grade 3 toxicity occurrence may be related to high plasma sorafenib exposure. This supports the need for therapeutic drug monitoring to prevent toxicity grade 3 occurrence and therefore optimize the clinical management of patients under sorafenib. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Billemont
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - M. Hornecker
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - S. Ropert
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - B. Blanchet
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - J. Jais
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - P. Blanchard
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - J. Meric
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - J. Alexandre
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - M. Tod
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| | - F. Goldwasser
- Cochin Hospital, Paris, France; Necker Enfants Malades Hospital, Paris, France; Centre Médical de Bligny, Briis sous Forges, France
| |
Collapse
|